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ORIGINAL ARTICLE
Background/Aims: Helicobacter pylori (H. pylori) infection appears to subvert the human iron regulatory
mechanism and thus upregulates hepcidin, resulting in unexplained iron-deficiency anemia (IDA). We evaluated
serum prohepcidin levels before and after eradication of H. pylori in IDA patients to assess whether it plays a role
in IDA related to H. pylori infection.
Methods: Subjects diagnosed with unexplained IDA underwent upper gastrointestinal endoscopy and
colonoscopy to confirm H. pylori infection and to exclude gastrointestinal bleeding. Blood was sampled before
treatment to eradicate H. pylori and again 1 month later. Serum prohepcidin levels were measured using a
commercial enzyme-linked immunosorbent assay kit.
Results: Serum prohepcidin levels decreased significantly after oral iron replacement combined with H. pylori
eradication (p = 0.011). The reduction ratio of serum prohepcidin levels after the treatment did not differ among
the combined oral iron replacement and H. pylori eradication groups, the H. pylori eradication only group, and the
iron replacement only group (p = 0.894). 
Conclusions: Serum prohepcidin levels decrease after both H. pylori eradication and oral iron administration,
with improvement in IDA. Serum concentration of prohepcidin is related to the anemia status, rather than to the
current status of H. pylori infection, in IDA patients. (Korean J Intern Med 2010;25:195-200)
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INTRODUCTION
Helicobacter pylori (H. pylori) requires iron to survive
and may potentially be associated with unexplained iron-
deficiency anemia (IDA) [1]. The prevalence of H. pylori
infection in refractory IDA is higher than in the normal
population [2], and an association between low serum
ferritin levels and a high prevalence of H. pylori-specific
IgG has been noted [3]. H. pylori-related refractory IDA
can be reversed by eradication of H. pylori [4], and some
H. pylori-infected IDA patients achieve normal serum
hemoglobin levels after H. pylori eradication, even without
oral iron treatment [5]. Additionally, it has been shown
that combined H. pylori eradication and iron replacement
produces a faster response than iron therapy alone [6].
Based on these findings, eradication of H. pylori is
recommended in unexplained IDA patients [7], although
no association between the pathogenesis of IDA and
H. pylori infection has yet been established. A key
pathogenic connection must exist to explain the relation-
ship between H. pylori infection and IDA, as not all
H. pylori-infected patients develop unexplained IDA.
Hepcidin, a 25-amino-acid disulfide-rich peptide that
is synthesized in the liver, acts as a systemic iron regulatory
hormone and plays an important role in duodenal iron
absorption [8]. Hepcidin mRNA is induced by interleukin-6[9], and its expression is enhanced by factors such as
lipopolysaccharides and Streptococcus iniae infection
[10]. Hepcidin binds to cell-surface ferroportin to trigger
its tyrosine phosphorylation, internalization, and
ubiquitin-mediated degradation in lysosomes, resulting
in the retention of iron in enterocytes and the interruption
of iron release from macrophages [11]. In murine models,
parenchymal iron deposition has been reported in
hepcidin knockout mice [12], whereas transgenic mice
that overexpress hepcidin exhibited decreased body iron
levels and presented with severe IDA [13]. Additionally,
H. pylori subverts the human iron regulatory mechanism
in a manner that is beneficial to H. pylori, but deleterious
to the host, by inducing the up-regulation of hepcidin
and/or down-regulation of ferroportin [14].
Attempts to produce correctly folded synthetic hepcidin
have proved difficult. Thus, prohepcidin, the 60-amino
acid product of the cleavage of the signal peptide from the
hepcidin precursor, is measured with a currently available
commercial assay for bioactive hepcidin analysis [15]. To
determine the feasibility of serum prohepcidin as a useful
biomarker in IDA, it is first necessary to determine the
precise molecular mechanism underlying the action of
prohepcidin under various conditions. In this study, we
evaluated changes in serum prohepcidin levels before
and after H. pylori eradication in H. pylori-infected IDA
patients to establish whether it normalized after treatment.
METHODS
Patients
Subjects diagnosed with unexplained IDA at the
Division of Hematology at Konkuk University Medical
Center between October 2006 and March 2008 were
asked to participate in the study. Upper gastrointestinal
endoscope and colonoscope examinations were performed
to exclude any source of gastrointestinal bleeding. Other
exclusion criteria were: 1) patients with chronic inflam-
matory disease, infection, recent bleeding, or malignancy,
2) subjects who had previously undergone H. pylori
eradication, or 3) subjects who had taken regular iron
supplement therapy within the most recent 3 months.
Blood was sampled before treatment to eradicate H.
pylori and again 1 month later for hemoglobin, hematocrit,
iron (Fe), total iron binding capacity (TIBC), ferritin,
and serum pro-hepcidin levels. 
This prospective study was approved by the institutional
review board of Konkuk University Medical Center. All
subjects provided written informed consent before the
study.
Diagnosis and treatment for H. pylori infection 
Positivity for H. pylori infection was recorded when one
of the following tests was positive: 1) histology with
hematoxylin and eosin staining and Giemsa staining, 2)
rapid urease by a CLOtest, or 3) a serum antibody test. For
the first eradication, amoxicillin 1 g, clarithromycin 500
mg, and a proton pump inhibitor 20 mg were given twice
a day for 7 days. Four weeks after eradication, a urease
breath test was carried out; if it was positive, a second
eradication was performed with tetracycline 500 mg and
bismuth 300 mg four times a day, metronidazole 500 mg
three times a day, and a proton pump inhibitor twice a day
for a week. The urease breath test was performed again after
4 weeks of eradication.
Measurement of serum prohepcidin levels
Whole blood samples were centrifuged (2,000 × g, 5
minutes), aliquoted, and kept frozen at -80˚C until
assayed. Levels of serum prohepcidin were determined by
an enzyme-linked immunosorbent assay based on a
competitive principle (DRG International Inc., Mountainside,
NJ, USA) according to the manufacturer’s protocol.
Optical densities were read with a Bio-Rad PhDTM
system (Bio-Rad Laboratories, Hercules, CA, USA). A
standard curve was automatically constructed using a
4parameter logistics curve fit with Bio-Rad PhDTM
system (Bio-Rad Laboratories), and the corresponding
concentrations of patient samples were calculated from
the standard curve. All standards, subject samples, and
controls were run in duplicate, and individual samples
with a coefficient of variation for paired replicates of
more than 15.0% were retested. The reduction ratio was
determined by dividing the prohepcidin level after the
treatment by the initial prohepcidin level.
Statistical analyses
Differences between pre-treatment and post-treatment
levels were analyzed using the Wilcoxon signed rank test.
Differences between H. pylori-infected and noninfected
groups were analyzed using the chi-squared test and
Student’s t test, and comparisons among three groups
were done by analysis of variance (ANOVA). Fe and
ferritin were analyzed using the Kruskal-Wallis test and
are presented as median values. Age, hemoglobin, hematocrit,
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means ± standard deviations (SD). All increment and
decrement ratios were determined by dividing the serum
level after 4 weeks of treatment by the initial serum level
before treatment. Analysis of covariance was carried out to
compare the changes of prohepcidin levels before and
after treatment among the groups. A probability value of
p< 0.05 was deemed to indicate statistical significance. 
RESULTS
Of the 50 initially enrolled subjects, 12 were excluded
because the cause of their IDA was established (Fig. 1). Of
the 38 remaining IDA subjects, 29 subjects (76.3%)
revealed H. pylori infection. Eradication was conducted in
these 29 subjects, but six refused to participate in the
study after the treatment. Baseline characteristics did not
differ between the remaining 23 H. pylori-infected
subjects (212.9 ± 88.2 ng/mL) and nine non-infected
subjects (217.8 ± 56.2 ng/mL, p = 0.879, Table 1). Of 23
H. pylori-infected subjects, six patients preferred to
undergo H. pylori eradication without iron replacement
based on their past experiences of severe adverse effects
during iron intake. Thus, only 17 H. pylori-infected IDA
subjects underwent combined H. pylori eradication and
iron replacement.
Serum prohepcidin levels before and after 
treatment 
In the 17 subjects who underwent oral iron therapy with
successful H. pylori eradication, serum prohepcidin level
decreased from 200.8 ± 80.8 ng/mL (mean ± SD) to
170.4 ± 67.6 ng/mL after 4 weeks of treatment (p= 0.011).
Of the 17 subjects, eradication of H. pylori failed with the
first-line therapy in two, and thus second-line eradication
was conducted. At 4 weeks, all showed negative urease
breath tests. 
Mean serum prohepcidin levels decreased in the six
subjects who underwent H. pylori eradication alone
(247.2 ± 107.0 ng/mL to 200.1 ± 69.4 ng/mL, p = 0.075)
and in the nine noninfected subjects who took oral iron
therapy alone (217.8 ± 56.2 ng/mL to 188.7 ± 52.4 ng/mL,
p = 0.086). With regard to the reduction ratio of serum
prohepcidin levels after treatment, no significant difference
Lee SY, et al. Prohepcidin levels in Helicobacter pylori infected IDA    197
Table 1. Baseline characteristics of the Helicobacter pylori-infected and noninfected patients with IDA
H. pylori-infected IDA patients Noninfected IDA patients p value
(n = 23) (n = 9)
Gender (female / male) 21 / 2 9 / 0 0.377
Age, yr 37.55 ± 11.06 44.22 ± 15.94 0.191
Hemoglobin, g/dL 8.23 ± 1.70 8.67 ± 1.73 0.513
Hematocrit, % 27.67 ± 4.55 28.96 ± 4.78 0.482
Fe, µg/dL (range) 12 (6 - 22) 17 (6 - 47) 0.231a
TIBC, µg/dL 435.22 ± 62.00 406.00 ± 64.44 0.245
Ferritin, ng/mL (range) 3.43 (0.93 - 24.8) 3.48 (1.29 - 84.99) 0.630a
Prohepcidin, ng/mL 212.92 ± 88.20 217.80 ± 56.20 0.879
Values are presented as mean ± SD.
IDA, iron-deficiency anemia; Fe, iron; TIBC, total iron binding capacity.
aKruskal-Wallis test.
Figure 1. Study flow of the subjects. Of 50 subjects, 12 were
excluded because the causes of iron-deficiency anemia were
found. Of 29 Helicobacter pylori (H. pylori)-infected subjects,
six did not return after 4 weeks of treatment. Thus, only 23 H.
pylori-infected subjects and nine non-infected subjects were
analyzed. IDA, iron-deficiency anemia.
50 IDA patients agreed on participation and underwent evaluation
12 were excluded due to
- 6 gynecologic diseases 
- 3 peptic ulcers
- 3 others 
6 were excluded due to
follow up loss after
H. pylori eradication  
29  had H. pylori
infection and underwent
eradication therapy 
23 revealed H. pylori
negative after
eradication therapy
9  had no
H. pylori infection
17 underwent
oral iron  therapy
6 did not undergo
oral iron therapyamong the groups after treatment (p = 0.8936, Table 2).
Although the reduction ratio value in the H. pylori
eradication alone group (0.86 ± 0.21) was lower than that
in the H. pylori eradication group with iron replacement
(0.88 ± 0.21) and that in the iron replacement only group
(0.88 ± 0.18), the difference was not statistically significant
(p= 0.8936). 
Long-term follow-up after H. pylori eradication
Of the 17 subjects who underwent combined oral iron
replacement and H. pylori eradication, nine were followed
at the outpatient clinic at least for 3 months (Table 3). All
showed a decrease in serum prohepcidin levels (Fig. 2)
with improvement in IDA.
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Table 2. Changes in laboratory blood tests before and after 4 weeks of treatment
Valiables Helicobacter pylori  Helicobacter pylori Iron replacement p value
eradication with iron eradication alone  alone 
replacement  (n = 6) (n = 9)
(n = 17)
Gender (female / male) 16 / 1 5 / 1 9 / 0 0.424
Increment ratio of hemoglobin level 1.35 ± 0.34 1.15 ± 0.20 1.23 ± 0.23 0.416
Increment ratio of hematocrit level  1.25 ± 0.22 1.16 ± 0.20 1.20 ± 0.21 0.716
Increment ratio of Fe level (range) 3.48 (0.92 - 15.73) 2.74 (0.67 - 5.88) 5.80 (2.38 - 9.67) 0.267a
Decrement ratio of TIBC level 0.93 ± 0.20 1.09 ± 0.09 1.02 ± 0.09 0.258
Increment ratio of ferritin level (range) 3.58 (0.27 - 11.48) 0.90 (0.63 - 1.06) 3.39 (0.32 - 10.95) 0.173a
Decrement ratio of prohepcidin levelb 0.86 ± 0.21 0.88 ± 0.21 0.88 ± 0.18 0.894
Values are presented as mean ± SD.
Fe, iron; TIBC, total iron binding capacity.
aKruskal-Wallis test.
bDecrement ratio is determined by dividing the serum level after 4 weeks of treatment by the initial serum level before treatment. 
Figure 2. Serum prohepcidin levels measured over a long term
follow up period. Of 17 subjects who underwent successful
Helicobacter pylori eradication and iron replacement therapy,
nine were followed for more than 3 months. Serum prohepcidin
levels continued to decrease in all nine subjects with improvement
in iron-deficiency anemia.
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Table 3. Long-term follow-up results of nine subjects after combined Helicobacter pylori eradication and iron
replacement therapy
Age, yr /  Initial hemoglobin,  Initial ferritin,  Follow-up  Latest hemoglobin, Latest ferritin, Reduction ratio of 
gender g/dL ng/mL period, mon g/dL ng/mL prohepcidin level
40 / F 8.4 2.39 10 14.0 36.63 0.952
48 / F 8.2 2.52 5 12.8 36.22 0.815
43 / F 10.2 3.43 6 14.6 49.02 0.383
52 / F 7.8 2.40 6 11.0 5.26 0.493
40 / F 7.7 3.48 6 12.8 37.06 0.887
25 / F 8.1 1.22 16 13.8 12.45 0.627
49 / F 9.5 4.69 3 9.8 2.93 0.557
37 / F 8.1 2.77 9 13.2 47.78 0.773
40 / F 8.5 3.20 5 10.5 4.1 0.987DISCUSSION
In this study, we measured only the serum prohepcidin
level because of the difficulty inherent in measuring serum
hepcidin. Although we were unable to measure hepatic
iron accumulation in each case because that would involve
an invasive procedure, our data suggest that serum
prohepcidin levels were increased in patients with IDA
regardless of the presence of H. pylori infection. To our
knowledge, this is the first reported study to measure
serum prohepcidin levels in IDA patients, comparing
levels before and after H. pylori eradication with or
without iron replacement.
Serum prohepcidin levels decreased significantly in the
H. pylori-infected IDA patients after combined H. pylori
eradication and oral iron therapy. Additionally, a tendency
toward a decrease in serum prohepcidin levels after H.
pylori eradication or iron replacement was observed. Our
findings may be explained by the suggestion made in
previous work that H. pylori infection results in the
regulation of hepcidin, which prevents a response to oral
iron and manipulates the host’s iron homeostasis to
ensure its survival [14,16]. Notably, six H. pylori-infected
subjects who declined to take oral iron also exhibited a
reduction in serum prohepcidin levels after H. pylori
eradiation. It seems that iron therapy is not required in H.
pylori-infected IDA patients, as it appears that the IDA
can be cured merely by eradicating the H. pylori infection
[5]. However, serum prohepcidin levels decreased further
with combined H. pylori eradication and oral iron
replacement. This is consistent with a previous study that
found that combined H. pylori eradication and iron
replacement produced a faster response than iron therapy
alone [6].
The serum concentration of prohepcidin in Korean
female college students has been reported to be 85.1 ± 6.1
ng/mL, with a range of 13.6 to 295.7 mg/mL [17]. Serum
prohepcidin levels in our IDA patients were significantly
higher than this value, regardless of the presence of
H. pylori infection. We are unable to explain the lack of
difference in serum pro-hepcidin levels between the H.
pylori-infected and noninfected groups before treatment.
We suggest that long-term infection with H. pylori leads
to homeostasis in IDA patients because most are infected
during childhood. Interestingly, serum prohepcidin levels
exhibited a tendency to decrease in the noninfected IDA
group after oral iron therapy, suggesting that hepcidin is
an important mediator of iron homeostasis even in
noninfected IDA. During long-term follow-up observation
for more than 3 months, the prohepcidin levels in nine
subjects decreased further after successful H. pylori
eradication therapy as IDA improved with continuous oral
iron replacement. This indicates that the serum
prohepcidin level does not normalize immediately.
Our study has several limitations. First, no long-term
follow-up data were gathered in the H. pylori-eradication
only group or the iron-replacement only group. Second,
we did not check intragastric acid levels in each subject,
although a possibility of achlorhydria exists due to H.
pylori-induced chronic pangastritis. Third, most of the
subjects were premenopausal women; indeed, only two
men were included in the study. Most male subjects were
ruled out from unexplained IDA because they showed
positive findings in upper or lower gastrointestinal
endoscopy.
In summary, our findings suggest that serum prohep-
cidin levels are related to the severity of IDA, rather than
to the presence of H. pylori infection, for the following
reasons. First, basal serum prohepcidin levels were higher
in our IDA patients than reported for normal healthy
Koreans regardless of H. pylori infection status [17].
Second, serum prohepcidin levels decreased after iron-
replacement therapy, even in the noninfected group.
Third, during longterm followup after successful H. pylori
eradication, serum prohepcidin levels decreased further
with improvement in the IDA. Fourth, no significant
difference in the reduction ratios was found among the
three groups, although combined H. pylori eradication
and iron replacement therapy seemed to have a synergistic
effect. Fifth, either H. pylori eradication or oral iron
administration resulted in decreased serum prohepcidin
levels after the treatment, accompanied by IDA improve-
ment. Taken together. Taken together, these findings
indicate that the serum concentration of prohepcidin is
related to the status of anemia rather than to the current
status of H. pylori infection in IDA patients, indicating
that serum concentration of prohepcidin is a functional
measure in IDA.
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